Richard Horton ridiculed over primitive surgical research methods in a famous commentary in the Lancet more than two decades ago [9] . Surgical research was compared with a comic opera-where questions are shouted out, but without answers. Horton stated BI should like to shame [surgeons] out of the comic opera performances which they suppose are statistics of operations.^The dominating study method in neurosurgery, namely retrospective series of surgeons evaluating their own work is often hopelessly biased and the scientific value may certainly be questioned. Without well-conducted randomized controlled trials (RCTs), can we really advance and know what works and what does not? And before we discuss the optimal surgical management, do we really know that surgery helps at all? Surgery has traditionally been more experience based than evidence based, and much of the enormous advancements in of surgical treatment over the last 200 years have taken place without rigorous scientific trials [6] . Still, there are several thought-provoking examples of surgical interventions that have failed the test of a sham-controlled randomized trial, for example arthroscopic knee surgery for degenerative osteoarthrosis or meniscal tears [15, 20] , subacromial decompression for shoulder impingement [17] , diaphragm pacing in ALS [7] , deep brain stimulation in the ventral capsule/ventral striatum for depression [5] , renal denervation for hypertension [1] , and vertebroplasty for osteoporotic vertebral fractures [2] . In fact, an overwhelming majority of sham-controlled trials in surgery fail to demonstrate an effect of the intervention [18] . Does this mean that surgery often is less effective than we like to believe? Or does it merely reflect the fact that few surgical interventions can be placebo controlled and that such trials are more often done when the likelihood of surgery being an effective treatment is low in the first place? Nevertheless, very few surgical treatments have been placed under the scrutiny of such trials and many operations are still backed by relative scarce and often conflicting evidence, not at least in neurosurgery.
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Martin and colleagues [14] conducted an interesting and well-written systematic review with critical appraisal of RCTs that compare neurosurgical interventions with nonoperative therapy. They identified 82 neurosurgical RCTs published between 2000 and 2017. More than a third of the trials found a difference between operative and non-operative treatment, but in less than 4% non-operative management was found to be superior. However, most trials were conducted by surgeons, and this can be a source of bias as the genealogy of scientist may have an impact on their findings [8] . Further, high JADAD score, reflecting better methodological quality [10] , was associated with lower chance of demonstrating a benefit from surgery. The JADAD scale places much emphasis on blinding and the inter-rater agreement for the JADAD scale has been questioned [3] . Still, almost half of the neurosurgical studies in the current review had a JADAD score of 1 or 2, indicating rather poor quality. Further, study protocols were properly registered in less than half of the trials, and among the registered trials, 13% and 34% had changed the primary or secondary endpoint between trial registration and publication. These findings are in line with previous reports [12, 13] , but the results are still concerning. RCTs crown the pyramid of evidence and may change clinical practice. However, can we trust the surgical RCTs-and is RCT design really the best study design in surgery? Perhaps we are giving many surgical RCTs too much credit? Or are we simply not planning and conducting these trials well enough?
A rigorous and well-conducted RCT has several advantages. First, following a strict and published study protocol avoids post hoc (or ad hoc) result driven explorations of different endpoints and case selections. Second, the by default prospective study design ensures that assessments, documentation, and follow-up can be uniform and planned. Third, This article is part of the Topical Collection on Neurosurgery general randomization or planned cross-over ensures that known or unknown prognostic factors (or confounders) are equally distributed between cases and controls. Forth, blinding ensures that potential bias associated with assessment, reporting, or analyzes can be minimalized. In the most extensive form, so-called quadruple blinding, both the patients, the study team, the outcome evaluators, and data analysts are blinded to what treatment was given. The study paper may then be written up until the discussion section before the seal is broken and the allocation is revealed. Although this rigorous form of RCTs might be feasible if comparing two white pills with similar dose repetitions and side effects, most surgical RCTs are associated with several weaknesses that are difficult to overcome. First, timing and planning of surgical RCTs are difficult since surgical methods evolve gradually over time and too early rigorous assessments may be unfair to the evolving methods which few surgeons yet master while clinical equipoise may be lost if evaluations are done too late. Also, standardization of interventions may be difficult as surgeons are trained differently, improvise, and may develop their surgical technique over time. Also, perioperative care and surveillance are often different between different departments and may be tailored in given patients. Drug trials are usually conducted in phases where endpoints, statistical power, and adverse effects are first explored in smaller phase II RCTs before the lager multicenter phase III trials are carried out. Marketing is generally not allowed before the phase III trial is finished. Conversely, surgical RCTs are usually not done in stages and choosing the most appropriate endpoints and estimations about effect sizes and statistical power can therefore be difficult. As a result, most surgical RCTs are comparable with phase II drug trials and are therefore small and sometimes more explorative in nature. This increases the likelihood of both false positive and false negative finding. After these smaller phase II-like surgical trials are done, clinical equipoise is perhaps not there anymore and validation studies and larger multicenter studies are seldom conducted. Second, recruitment may be problematic. Patients are often more reluctant towards invasive, risky, and non-reversible interventions if the treating physician has no clear treatment recommendation. Also, operative treatments are usually not as common as drug treatments, and this affects recruitment, market value, and funding opportunities. This may further contribute to underpower and false negative findings. Third, pre-inclusion bias may be problematic, not at least in studies comparing surgery with non-operative treatment. Often, patients referred to surgery have already tried several non-operative treatments. This may introduce expectation bias and reduce the likelihood of demonstrating an effect of further non-operative management. Third, cross-over is often a major problem, not at least when comparing surgery with non-operative management. For example, the SPORT study on surgical vs. non-operative treatment for lumbar disc herniation, 60% assigned to surgery had been operated at 2 years compared with 45% of patients randomized to non-operative treatment [22] . Thus, intention-totreat analyses were much obscured and the trial ended up more observational than interventional in the end.
Perhaps the most important weakness associated with surgical trials is difficulty with blinding. In a systematic review of 250 RCTs, researchers observed considerable differences in treatment effects between trials that reported Bdoubleblinding^compared with those that did not [19] . However, the surgeon can usually not be blinded and sham-controlled interventions are seldom feasible, especially if comparing with non-operative treatments. Thus, the great majority of such trials are open label. As the placebo (and perhaps also nocebo) effects of various interventions vary, this weakness is significant and often difficult to overcome. This is especially problematic with subjective and patient-reported endpoints and short follow-ups. Further, difference in follow-up routines or surveillance between the two treatment arms is not uncommon if comparing completely different treatment modalities. This may have large effects on its own, also on hard endpoints. For example, a recent study in lung cancer patients randomized to either continuous web-based symptom monitoring with patient reported outcomes or standard follow-up with scheduled imaging every 3 to 6 months demonstrated a large survival difference, median 22.5 months vs. 14.9 months [4] .
Due to the aforementioned points, surgical RCTs usually cannot fulfill many of the important quality traits of the ideal and gold standard RCT. Consequently, the overall methodological quality is often poor, as seen in the review by Martin and colleagues [14] . According to Oxford Center for Evidence Based Medicine, the obtainable level of evidence from a poor quality RCT is not better than a well-conducted cohort study, namely level 2b (https://www.cebm.net/). At times, a good cohort study can even be more informative than a poor quality RCT. In fact, many of the important quality traits of RCTs can (and should) be copied in well-designed cohort studies. Like an RCT, a good cohort study is prospective in nature. In the lack of randomization, propensity matching can, for example be, done to limit selection bias [16] . Also, differences in favored treatments between centers may enable pseudorandomized trials [11] . Collection of prospective data, for example within treatment registries may enable parallel cohort studies or pragmatic trials with sufficient statistical power. Also, the study team, outcome evaluators, or data analysts may be blinded. Further, while the generalizability of RCTs can be limited by strict inclusion and exclusion criteria, cohort studies may capture the clinical effectiveness in everyday patients. Registration of protocols, before data is retrieved, is unfortunately still not required in observational studies, but would be a major strength to limit or expose explorative data analyses. However, while many journals embrace the STROBE statement (or checklist) for observational studies [21] , these requirements only deal with transparency of reporting.
Although many surgical RCTs may reach a glass ceiling on the climb up the hierarchy of evidence, many of these trials still deserve considerable impact, not at least in comparison with the rather primitive conventional study methods in surgery. Even so, there is great potential for improving study designs in surgery, not at least for cohort studies.
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